It is known that cancer cells generally adapt a specific metabolic phenotype that is characterized by the switch to aerobic glycolysis, or Warburg Effect. While this metabolic phenotype is largely believed to be responsible for the growth advantage of various cancers, the underlying mechanisms are not very clear. This talk will be focused on our current progress related to cMyc-mediated epigenetic regulation of cancer metabolic reprogramming.